Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes. The company was incorporated in 2012 and is headquartered in Newport Beach, California. Show more

520 Newport Center Drive, Newport Beach, CA, 92660, United States

Drug Manufacturers - Specialty & Generic

Healthcare

Market Cap

326M

52 Wk Range

$4.09 - $13.66

Previous Close

$4.91

Open

$4.96

Volume

936,686

Day Range

$4.83 - $5.03

Enterprise Value

427.6M

Cash

53.83M

Avg Qtr Burn

N/A

Insider Ownership

16.44%

Institutional Own.

76.19%

Qtr Updated

12/31/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Evolysse™ Details Nasolabial fold lines	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Jeuveau (prabotulinumtoxinA-xvfs) Details Glabellar lines , Benign tumor	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Jeuveau “Extra-Strength” Details Glabellar lines	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.